CareDx Reports Preliminary Financial Results for Third Quarter 2024
CareDx, Inc. (Nasdaq: CDNA) reported preliminary financial results for the third quarter of 2024. The company expects:
- Revenue between $82-83 million, up ~23% year-over-year
- Testing Services volume of ~44,600, up ~16% year-over-year
- Testing services revenue of $60-61 million, up ~26% year-over-year
- Patient and Digital Solutions revenue of ~$11.9 million, up 20% year-over-year
- Products revenue of ~$10.2 million, up 7% year-over-year
CareDx ended the quarter with ~$240 million in cash, cash equivalents, and marketable securities, with no debt. The company will report full Q3 2024 results on November 4, 2024, after market close, followed by a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
CareDx, Inc. (Nasdaq: CDNA) ha riportato risultati finanziari preliminari per il terzo trimestre del 2024. L'azienda prevede:
- Ricavi tra $82-83 milioni, in aumento di circa il 23% rispetto all'anno precedente
- Volume dei servizi di test di circa 44.600, in aumento di circa il 16% rispetto all'anno precedente
- Ricavi dai servizi di test di $60-61 milioni, in aumento di circa il 26% rispetto all'anno precedente
- Ricavi da soluzioni per pazienti e digitali di circa $11,9 milioni, in aumento del 20% rispetto all'anno precedente
- Ricavi da prodotti di circa $10,2 milioni, in aumento del 7% rispetto all'anno precedente
CareDx ha concluso il trimestre con circa $240 milioni in contante, equivalenti di contante e titoli negoziabili, senza debito. L'azienda presenterà i risultati completi del Q3 2024 il 4 novembre 2024, dopo la chiusura del mercato, seguiti da una conferenza telefonica alle 13:30 ora del Pacifico / 16:30 ora dell'Est.
CareDx, Inc. (Nasdaq: CDNA) informó resultados financieros preliminares para el tercer trimestre de 2024. La compañía espera:
- Ingresos entre $82-83 millones, un aumento de aproximadamente el 23% interanual
- Volumen de Servicios de Pruebas de aproximadamente 44,600, un aumento de aproximadamente el 16% interanual
- Ingresos por servicios de pruebas de $60-61 millones, un aumento de aproximadamente el 26% interanual
- Ingresos de Soluciones para Pacientes y Digitales de aproximadamente $11.9 millones, un aumento del 20% interanual
- Ingresos por productos de aproximadamente $10.2 millones, un aumento del 7% interanual
CareDx finalizó el trimestre con aproximadamente $240 millones en efectivo, equivalentes de efectivo y valores negociables, sin deudas. La compañía informará los resultados completos del Q3 2024 el 4 de noviembre de 2024, después del cierre del mercado, seguido de una conferencia telefónica a la 1:30 p.m. Hora del Pacífico / 4:30 p.m. Hora del Este.
CareDx, Inc. (Nasdaq: CDNA)는 2024년 3분기 예비 재무 결과를 보고했습니다. 회사는 다음을 예상하고 있습니다:
- 수익: $82-83 백만, 전년 대비 약 23% 증가
- 테스트 서비스 볼륨: 약 44,600, 전년 대비 약 16% 증가
- 테스트 서비스 수익: $60-61 백만, 전년 대비 약 26% 증가
- 환자 및 디지털 솔루션의 수익: 약 $11.9 백만, 전년 대비 20% 증가
- 제품 수익: 약 $10.2 백만, 전년 대비 7% 증가
CareDx는 약 $240 백만의 현금, 현금성 자산 및 유가증권을 보유하고 있으며, 부채는 없습니다. 회사는 2024년 11월 4일 시장 마감 후 Q3 2024의 전체 결과를 보고하고, 태평양 표준시 기준 오후 1:30 / 동부 표준시 기준 오후 4:30에 전화 회의를 진행할 것입니다.
CareDx, Inc. (Nasdaq: CDNA) a annoncé des résultats financiers préliminaires pour le troisième trimestre de 2024. La société s'attend à :
- Un chiffre d'affaires entre 82 et 83 millions de dollars, en hausse d'environ 23 % par rapport à l'année précédente
- Un volume de services de tests d'environ 44 600, en hausse d'environ 16 % par rapport à l'année précédente
- Un chiffre d'affaires provenant des services de tests de 60 à 61 millions de dollars, en hausse d'environ 26 % par rapport à l'année précédente
- Un chiffre d'affaires des solutions pour les patients et numériques d'environ 11,9 millions de dollars, en hausse de 20 % par rapport à l'année précédente
- Un chiffre d'affaires des produits d'environ 10,2 millions de dollars, en hausse de 7 % par rapport à l'année précédente
CareDx a terminé le trimestre avec environ 240 millions de dollars en liquidités, équivalents de liquidités et titres négociables, sans dettes. La société publiera les résultats complets du T3 2024 le 4 novembre 2024, après la fermeture des marchés, suivis d'une conférence téléphonique à 13h30 heure du Pacifique / 16h30 heure de l'Est.
CareDx, Inc. (Nasdaq: CDNA) berichtete über vorläufige finanzielle Ergebnisse für das dritte Quartal 2024. Das Unternehmen erwartet:
- Einnahmen zwischen 82-83 Millionen USD, eine Steigerung von etwa 23% im Jahresvergleich
- Testdienstleistungsvolumen von etwa 44.600, eine Steigerung von etwa 16% im Jahresvergleich
- Einnahmen aus Testdiensten von 60-61 Millionen USD, eine Steigerung von etwa 26% im Jahresvergleich
- Einnahmen aus Patienten- und digitalen Lösungen von etwa 11,9 Millionen USD, ein Anstieg von 20% im Jahresvergleich
- Produkteinnahmen von etwa 10,2 Millionen USD, ein Anstieg von 7% im Jahresvergleich
CareDx schloss das Quartal mit etwa 240 Millionen USD an Bargeld, Zahlungsmitteln und handelbaren Wertpapieren, ohne Schulden ab. Das Unternehmen wird die vollständigen Ergebnisse des Q3 2024 am 4. November 2024 nach Börsenschluss bekannt geben, gefolgt von einer Telefonkonferenz um 13:30 Uhr Pazifischer Zeit / 16:30 Uhr Eastern Time.
- Revenue expected to increase by approximately 23% year-over-year
- Testing Services volume grew by approximately 16% year-over-year
- Testing services revenue expected to increase by approximately 26% year-over-year
- Patient and Digital Solutions revenue up 20% year-over-year
- Products revenue up 7% year-over-year
- Strong cash position of approximately $240 million with no debt
- None.
Insights
CareDx's preliminary Q3 2024 results show strong growth across all business segments. Revenue is expected to be between
- Testing Services volume growth of
16% YoY to 44,600 tests - Testing Services revenue increase of
26% YoY to$60-$61 million - Patient and Digital Solutions revenue up
20% YoY to$11.9 million - Products revenue growth of
7% YoY to$10.2 million
The company's strong cash position of
CareDx's Q3 results demonstrate the increasing adoption of precision medicine in transplant care. The
The company's multi-pronged approach, covering testing services, digital solutions and products, positions it well to address various aspects of transplant care. The strong growth in Patient and Digital Solutions (
As the field of transplantation continues to evolve, CareDx's focus on developing clinically differentiated, high-value solutions puts it at the forefront of innovation in this specialized area of medicine. The sustained growth across all segments indicates that the company's offerings are gaining traction among healthcare providers and patients, potentially leading to improved transplant outcomes and patient care.
Third Quarter 2024 Financial Results to be Reported on November 4, 2024
Third Quarter 2024 Highlights
-
Third quarter revenue is expected to be in the range of
$82 million $83 million 23% year-over-year. -
Grew Testing Services volume to approximately 44,600, an increase of approximately
16% year-over-year. -
Testing services revenue is expected to be in the range of
$60 million $61 million 26% year-over-year. This includes approximately$1.2 million -
Patient and Digital Solutions revenue is expected to be approximately
$11.9 million $10.2 million 20% and7% year-over-year, respectively. -
Ended the quarter with cash, cash equivalents, and marketable securities of approximately
$240 million
The preliminary financial information presented in this press release is based on CareDx’s current expectations and may be adjusted as a result of, among other things, the completion of the quarterly review procedures of CareDx’s third quarter 2024 financial statements.
"We are pleased to report another quarter of growth across all our lines of business. Our performance continues to be strong as we head into the fourth quarter,” said John W. Hanna, CareDx President and CEO.
Upcoming Earnings Event
CareDx plans to report its third quarter 2024 financial results for the period ending September 30, 2024, on November 4, 2024, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
Individuals interested in listening to the conference call may do so by dialing 1-800-343-4849 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in
Forward Looking Statements
This press release includes forward-looking statements, including expectations regarding CareDx’s third quarter 2024 revenue, and cash, cash equivalents, and marketable securities as of September 30, 2024, its ability to advance transplant patient care, its prospects in 2024, and its anticipation to report third quarter 2024 financial results during its earnings call on November 4, 2024. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those projected, including the completion of quarterly review procedures off CareDx’s third quarter 2024 financial statements, and its current expectations, and general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015590407/en/
CareDx, Inc.
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investor@caredx.com
Source: CareDx, Inc.
FAQ
What is CareDx's expected revenue for Q3 2024?
How much did CareDx's Testing Services volume grow in Q3 2024?
What is CareDx's cash position at the end of Q3 2024?
When will CareDx (CDNA) report its full Q3 2024 financial results?
